Association between Hypercalcemia and Cardiovascular Disease using Cinacalcet

Abstract

Many scholars have reported that Hypercalcemia increases susceptibility to cardiovascular diseases. Cinacalcet, a calcimimetic agent, has been revealed to be a promising therapeutic agent for treating hypercalcemia and its cardiovascular consequences. The goal of this paper is to assess the effect of cinacalcet treatment on cardiovascular events in patients with HPT. Nineteen (19) randomised controlled trial studies published over the last 24 years were identified and incorporated into the study. The study demonstrated that cinacalcet lowered serum PTH, and calcium levels, which are primary factors in HPT and the general CVD incidence. The present review indicated that the number of cardiovascular events was significantly less than that of the control group. Regarding other safety issues, cinacalcet is associated with more risk regarding hypocalcemia, nausea, and vomiting. These outcomes bear the possibility of cinacalcet to manage HPT and its cardiovascular risks but also foresee the risk of side effects and the importance of monitoring and dose modification. This study recommends that more studies be conducted to evaluate the impact of cinacalcet, focusing on cardiovascular outcomes and overall mortality in the studied patient group.

Keywords: Cinacalcet, Hypercalcemia, Hyperparathyroidism, Cardiovascular disease, Parathyroid hormone